Mesenchymal stem/stromal cells in cancer therapy

Abstract The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone marrow in 1976, have been identified in nearly all tissues of human body now. The multipotency of MSCs allows them to give rise to osteocytes, chondrocytes, adipocytes, and other lineages. Moreover, armed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tianxia Lan, Min Luo, Xiawei Wei
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	MSC Immunomodulation Tumor-homing Therapeutic mechanism Signaling pathway Anticancer strategy Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f055f4a571a84585a96fc8eb442770e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f055f4a571a84585a96fc8eb442770e5
record_format	dspace
spelling	oai:doaj.org-article:f055f4a571a84585a96fc8eb442770e52021-11-21T12:02:27ZMesenchymal stem/stromal cells in cancer therapy10.1186/s13045-021-01208-w1756-8722https://doaj.org/article/f055f4a571a84585a96fc8eb442770e52021-11-01T00:00:00Zhttps://doi.org/10.1186/s13045-021-01208-whttps://doaj.org/toc/1756-8722Abstract The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone marrow in 1976, have been identified in nearly all tissues of human body now. The multipotency of MSCs allows them to give rise to osteocytes, chondrocytes, adipocytes, and other lineages. Moreover, armed with the immunomodulation capacity and tumor-homing property, MSCs are of special relevance for cell-based therapies in the treatment of cancer. However, hampered by lack of knowledge about the controversial roles that MSC plays in the crosstalk with tumors, limited progress has been made with regard to translational medicine. Therefore, in this review, we discuss the prospects of MSC-associated anticancer strategies in light of therapeutic mechanisms and signal transduction pathways. In addition, the clinical trials designed to appraise the efficacy and safety of MSC-based anticancer therapies will be assessed according to published data.Tianxia LanMin LuoXiawei WeiBMCarticleMSCImmunomodulationTumor-homingTherapeutic mechanismSignaling pathwayAnticancer strategyDiseases of the blood and blood-forming organsRC633-647.5Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	MSC Immunomodulation Tumor-homing Therapeutic mechanism Signaling pathway Anticancer strategy Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	MSC Immunomodulation Tumor-homing Therapeutic mechanism Signaling pathway Anticancer strategy Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tianxia Lan Min Luo Xiawei Wei Mesenchymal stem/stromal cells in cancer therapy
description	Abstract The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone marrow in 1976, have been identified in nearly all tissues of human body now. The multipotency of MSCs allows them to give rise to osteocytes, chondrocytes, adipocytes, and other lineages. Moreover, armed with the immunomodulation capacity and tumor-homing property, MSCs are of special relevance for cell-based therapies in the treatment of cancer. However, hampered by lack of knowledge about the controversial roles that MSC plays in the crosstalk with tumors, limited progress has been made with regard to translational medicine. Therefore, in this review, we discuss the prospects of MSC-associated anticancer strategies in light of therapeutic mechanisms and signal transduction pathways. In addition, the clinical trials designed to appraise the efficacy and safety of MSC-based anticancer therapies will be assessed according to published data.
format	article
author	Tianxia Lan Min Luo Xiawei Wei
author_facet	Tianxia Lan Min Luo Xiawei Wei
author_sort	Tianxia Lan
title	Mesenchymal stem/stromal cells in cancer therapy
title_short	Mesenchymal stem/stromal cells in cancer therapy
title_full	Mesenchymal stem/stromal cells in cancer therapy
title_fullStr	Mesenchymal stem/stromal cells in cancer therapy
title_full_unstemmed	Mesenchymal stem/stromal cells in cancer therapy
title_sort	mesenchymal stem/stromal cells in cancer therapy
publisher	BMC
publishDate	2021
url	https://doaj.org/article/f055f4a571a84585a96fc8eb442770e5
work_keys_str_mv	AT tianxialan mesenchymalstemstromalcellsincancertherapy AT minluo mesenchymalstemstromalcellsincancertherapy AT xiaweiwei mesenchymalstemstromalcellsincancertherapy
_version_	1718419339102650368

Mesenchymal stem/stromal cells in cancer therapy

Ejemplares similares